{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:45:55Z","timestamp":1765547155925,"version":"build-2065373602"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.canrad.2023.04.007","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T08:13:58Z","timestamp":1696580038000},"page":"66-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Radiation therapy of the primary tumour and\/or metastases of digestive metastatic cancers"],"prefix":"10.1016","volume":"28","author":[{"given":"F.","family":"Huguet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Riou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Modesto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Qu\u00e9ro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Michalet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bordron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Schipman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Orthuon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lisbona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Jaksic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2023.04.007_bib0365","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/jgh.13289","article-title":"Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis","volume":"31","author":"Njei","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0370","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.04.007_bib0375","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2023.04.007_bib0380","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2016.34.15_suppl.4050","article-title":"Prospective randomized phase II study of concurrent chemoradiotherapy versus chemotherapy alone in stage IV esophageal squamous cell carcinoma","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0385","first-page":"E138","article-title":"Definitive radiation therapy for patients with metastatic esophageal squamous cell carcinoma improves survival: an NCDB analysis","volume":"99","author":"Berriochoa","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.04.007_bib0390","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.athoracsur.2020.08.034","article-title":"The role of definitive radiation and surgery in metastatic esophageal cancer: an NCDB investigation","volume":"112","author":"Seyedin","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.canrad.2023.04.007_bib0395","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13014-018-1183-y","article-title":"Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study","volume":"13","author":"Lyu","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0400","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.canrad.2021.11.022","article-title":"Radiotherapy for cancers of the oesophagus, cardia and stomach","volume":"26","author":"Crehange","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.04.007_bib0405","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1038\/s41598-020-68160-6","article-title":"Development and validation of a nomogram prognostic model for esophageal cancer patients with oligometastases","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.canrad.2023.04.007_bib0410","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1245\/s10434-019-08175-0","article-title":"Clinicopathologic characteristics of oligometastases from esophageal cancer and long-term outcomes of resection","volume":"27","author":"Ohkura","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0415","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.21873\/anticanres.14164","article-title":"Stereotactic body radiotherapy for pulmonary oligometastases from esophageal cancer: results and prognostic factors","volume":"40","author":"Yamamoto","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2023.04.007_bib0420","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.radonc.2020.09.042","article-title":"Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer","volume":"154","author":"Li","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0425","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2020.05.003","article-title":"Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma","volume":"108","author":"Liu","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.04.007_bib0430","unstructured":"https:\/\/omecproject.eu\/ [Accessed November 12th 2022]."},{"key":"10.1016\/j.canrad.2023.04.007_bib0435","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejca.2022.02.018","article-title":"Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: a systematic review and meta-analysis","volume":"166","author":"Kroese","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2023.04.007_bib0440","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2021.11.032","article-title":"Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe","volume":"164","author":"Kroese","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2023.04.007_bib0445","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canrad.2023.04.007_bib0450","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0455","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.ejso.2018.11.006","article-title":"Oligometastatic gastric cancer: an emerging clinical entity with distinct therapeutic implications","volume":"45","author":"Salati","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0460","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0465","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial","volume":"3","author":"Al-Batran","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0470","first-page":"109","article-title":"Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: a nationwide population-based cohort study","volume":"37","author":"Kroese","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0475","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canrad.2023.04.007_bib0480","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0485","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.canrad.2023.04.007_bib0490","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Folfirinox versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.04.007_bib0495","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.04.007_bib0500","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1186\/s12885-019-6448-9","article-title":"Proposal for a definition of \u201coligometastatic disease in pancreatic cancer\u201d","volume":"19","author":"Damanakis","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2023.04.007_bib0505","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0510","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.3390\/cancers12113402","article-title":"Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: which role for conversion surgery? A systematic review and meta-analysis","volume":"12","author":"De Simoni","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canrad.2023.04.007_bib0515","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.surg.2021.12.029","article-title":"Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: an analysis of the National Cancer Database","volume":"171","author":"Hamad","year":"2022","journal-title":"Surgery"},{"key":"10.1016\/j.canrad.2023.04.007_bib0520","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1186\/s12885-021-08966-3","volume":"21","author":"Gebauer","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2023.04.007_bib0525","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.6004\/jnccn.2015.0079","article-title":"Management of the primary tumor and limited metastases in patients with metastatic pancreatic cancer","volume":"13","author":"Herman","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.canrad.2023.04.007_bib0530","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190627","article-title":"Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question","volume":"93","author":"Scorsetti","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0535","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ijrobp.2022.07.019","article-title":"Ablative radiation therapy in oligometastatic pancreatic cancer to delay polyprogression, limit chemotherapy, and improve outcomes","volume":"114","author":"Elamir","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.04.007_bib0540","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canrad.2023.04.007_bib0545","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.canrad.2023.04.007_bib0550","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.04.007_bib0555","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.semradonc.2018.06.007","article-title":"Radiation-induced liver disease and modern radiotherapy","volume":"28","author":"Koay","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0560","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0565","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.04.007_bib0570","doi-asserted-by":"crossref","first-page":"LBA01","DOI":"10.1016\/j.ijrobp.2022.09.002","article-title":"NRG\/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC)","volume":"114","author":"Dawson","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.04.007_bib0575","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41571-022-00655-9","article-title":"The oligometastatic spectrum in the era of improved detection and modern systemic therapy","volume":"19","author":"Katipally","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0580","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.3390\/cancers14184383","article-title":"The current role of stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC)","volume":"14","author":"Kimura","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canrad.2023.04.007_bib0585","doi-asserted-by":"crossref","first-page":"102258","DOI":"10.1016\/j.ctrv.2021.102258","article-title":"Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis","volume":"99","author":"Edeline","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.canrad.2023.04.007_bib0590","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.canrad.2022.06.031","article-title":"Stereotactic body radiotherapy of primary liver tumours: Indications and new techniques","volume":"26","author":"Bordeau","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2023.04.007_bib0595","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1748-717X-8-292","article-title":"Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma","volume":"8","author":"Kim","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0600","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s00432-020-03285-9","article-title":"Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity","volume":"146","author":"Franzese","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0605","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5114\/pg.2018.81072","article-title":"Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Gastroenterol Rev"},{"key":"10.1016\/j.canrad.2023.04.007_bib0610","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ctrv.2015.06.006","article-title":"Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus","volume":"41","author":"Adam","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.canrad.2023.04.007_bib0615","unstructured":"Th\u00e9saurus national de canc\u00e9rologie digestive."},{"key":"10.1016\/j.canrad.2023.04.007_bib0620","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/bjs.5346","article-title":"Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary","volume":"93","author":"Mentha","year":"2006","journal-title":"Br J Surg"},{"key":"10.1016\/j.canrad.2023.04.007_bib0625","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1245\/s10434-014-4069-8","article-title":"Rectal outcomes after a liver-first treatment of patients with stage IV rectal cancer","volume":"22","author":"Buchs","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0630","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2018.09.006","article-title":"Folfirinox as induction treatment in rectal cancer patients with synchronous metastases (RCSM): results of the FFCD 1102 phase II trial","volume":"104","author":"Bachet","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2023.04.007_bib0635","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1080\/0284186X.2016.1177201","article-title":"Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: long-term results of a phase II study","volume":"55","author":"Tyc-Szczepaniak","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0640","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0645","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/0284186X.2013.837582","article-title":"Palliative pelvic radiotherapy of symptomatic incurable rectal cancer\u00a0\u2013\u00a0a systematic review","volume":"53","author":"Cameron","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0650","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1748-717X-8-10","article-title":"Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma","volume":"8","author":"Zhu","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0655","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00384-015-2272-0","article-title":"Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy","volume":"30","author":"Kim","year":"2015","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.canrad.2023.04.007_bib0660","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdt124","article-title":"Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer","volume":"24","author":"van Dijk","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0665","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","article-title":"Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2","volume":"28","author":"G\u00e9rard","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0670","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","article-title":"Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial","volume":"29","author":"Aschele","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0675","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.canrad.2023.04.007_bib0680","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0685","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0690","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975356","article-title":"Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma","volume":"12","author":"Kim","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0695","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0700","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1200\/JCO.2020.38.15_suppl.4020","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: pooled results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0705","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0710","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.21037\/jgo-22-125","article-title":"Role of local therapy in the management of patients with metastatic anal squamous cell carcinoma: a National Cancer Database study","volume":"13","author":"Atallah","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.canrad.2023.04.007_bib0715","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijrobp.2018.04.076","article-title":"Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes","volume":"102","author":"Holliday","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.04.007_bib0720","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.canrad.2021.11.015","article-title":"Radiotherapy of anal canal cancer","volume":"26","author":"Peiffert","year":"2022","journal-title":"Cancer Radiother"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823002093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823002093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:39:12Z","timestamp":1761136752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321823002093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1278321823002093"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2023.04.007","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation therapy of the primary tumour and\/or metastases of digestive metastatic cancers","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2023.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}